Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial-Reference-Cited by-同舟云学术

Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial

Published:2011-04 Issue:2 Volume:11 Page:103-113
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Hamberg Paul,Bos Monique M.E.M.,Braun Hans J.J.,Stouthard Jacqueline M.L.,van Deijk Gert A.,Erdkamp Frans L.G.,van der Stelt-Frissen Iris N.,Bontenbal Marijke,Creemers Geert-Jan M.,Portielje Johanneke E.A.,Pruijt Johannes F.M.,Loosveld Olaf J.L.,Smit Willem M.,Muller Erik W.,Schmitz Paul I.M.,Seynaeve Caroline,Klijn Jan G.M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

2. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors;Berns;Eur J Cancer,1992

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

4. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer;Vogel;J Clin Oncol,2002

5. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule;Baselga;J Clin Oncol,2005

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of first‐line regimens for advanced HER2‐positive breast cancer: A Bayesian network meta‐analysis;Cancer Innovation;2024-05-22

2. HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments;Cancers;2023-03-13

3. Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer;The Egyptian Heart Journal;2023-02-13

4. Therapeutic landscape of advanced HER2-positive breast cancer in 2022;Medical Oncology;2022-10-12

5. Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients;The Breast;2021-10